Abstract: The invention provides a block copolymer comprising at least a first block and a second block. The first block comprises a plurality of temperature-sensitive monomeric units, a plurality of hydrophilic monomeric units and a plurality of targeting monomeric units, and the second block comprises a plurality of hydrophobic monomeric units. The second block comprises at least one pH-sensitive moiety.

Abstract: The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV conjugated to polymers, thereby forming conjugate molecules. The fusion peptide of the conjugate molecule comprises as component (I) N-terminally a GLP-1(7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. A synthetic polymer and/or a protein, e.g transferrin or albumin, is covalently or non-covalently bound to the fusion peptide to form the conjugate molecule. Component (II) is preferably a full or partial version of IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1(7-35, 36 or 37)/IP2/GLP-1(7-35, 36 or 37) or GLP-2 and a polymeric component, e.g. a natural or non-natural polymer. The fusion peptide may be produced in engineered cells or synthetically and is e.g.

Abstract: The present invention relates to biodegradable biocompatible polyketals, methods for their preparation, and methods for treating animals by administration of biodegradable biocompatible polyketals. In one aspect, a method for forming the biodegradable biocompatible polyketals comprises combining a glycol-specific oxidizing agent with a polysaccharide to form an aldehyde intermediate, which is combined with a reducing agent to form the biodegradable biocompatible polyketal. The resultant biodegradable biocompatible polyketals can be chemically modified to incorporate additional hydrophilic moieties. A method for treating animals includes the administration of the biodegradable biocompatible polyketal in which biologically active compounds or diagnostic labels can be disposed. The present invention also relates to chiral polyketals, methods for their preparation, and methods for use in chromatographic applications, specifically in chiral separations.

Abstract: A diagnostic kit disclosed herein comprises a nanoparticle-biomaterial complex, an extraction solution, a collection electrode, and a current peak measurement unit. The nanoparticle-biomaterial complex comprises: one or more nanoparticles selected from a metal group consisting of zinc, cadmium, lead, copper, gallium, arsenic, thallium, nickel, manganese and bismuth; one or more biomaterial-binding materials binding to the nanoparticles through a binding-stabilizing agent and binding specifically to the biomaterials to be detected; and a binding-stabilizing agent forming bonds between the nanoparticles and the biomaterial-binding materials. The extraction solution serves to isolate and extract the nanoparticles from the nanoparticle-biomaterial complex. The collection electrode serves to collect the nanoparticles from the extraction solution. The current peak measurement unit serves to measure current peaks corresponding to the nanoparticles collected from the collection electrode.

Abstract: A metal treatment composition including Tin (II) Chloride and processed montmorillonite clay. The addition of Tin (II) Chloride to the composition provides Tin for forming a ceramic-metal layer on the surfaces of the friction pair. Tin (II) Chloride provides Chlorine ions for forming Chloric films for protecting juvenile surfaces which form in the friction zone. The clay is heated and pulverized to produce a powder comprising both particles having crystalline layer structure and salts and oxides. The layered crystalline structure of the clay contains slip planes that transversely shift when tangential pressure from the friction pair is applied thereby lubricating the friction pair. The salts and oxides contribute to the formation of the ceramic-metal layer.

Abstract: The present invention relates to scaffolds composed of a protein backbone cross-linked by a synthetic polymer. Specifically, the present invention provides PEGylated-thiolated collagen scaffolds and PEGylated albumin scaffolds and methods of generating and using same for treating disorders requiring tissue engineering.

Abstract: Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided (among other things) are compositions comprising the conjugates, methods of making the conjugates, and methods of administering to a patient compositions comprising the conjugates.

Abstract: In various aspects provided are methods for producing a nanoparticle within a cross-linked, collapsed polymeric material. In various embodiments, the methods comprise (a) providing a polymeric solution comprising a polymeric material; (b) collapsing at least a portion of the polymeric material about one or more precursor moieties; (c) cross-linking the polymeric material; (d) modifying at least a portion of said precursor moieties to form one or more nanoparticles and thereby forming a composite nanoparticle.

Abstract: The present invention relates to shape memory materials and to a method for controlling shape change in shape memory materials. In particular, the invention relates to a method and a system for forming complex shapes from shape memory materials and to shape memory materials having complex shapes.

Abstract: The invention provides block copolymers formed of poly(ethylene glycol) segments and poly(amino acid derivative) segments having side chains of at least one kind of specific amine residue. The invention also provides polyion complexes of such copolymers with polynucleotides and the like. These block copolymers are useful as carriers for in vivo delivery of active substances such as DNA.

Abstract: Disclosed are reactive cyclic carbonates and ureas of formula (I) or (II), wherein R and X have the meaning indicated in the description. Said carbonates and ureas allow functional groups to be specifically introduced into biomolecules, polymers, and surfaces in mild conditions.

Abstract: Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided (among other things) are compositions comprising the conjugates, methods of making the conjugates, and methods of administering to a patient compositions comprising the conjugates.

Abstract: An affinity matrix comprising a base matrix containing biotin; and a fusion protein attached to the base matrix, wherein the fusion protein contains a matrix binding element capable of binding to the base matrix via biotin and a target binding element capable of binding, or being bound by, at least one target component.

Abstract: The present disclosure relates to a new polymerisation process in which ethylenically unsaturated monomers are polymerised by a living radical polymerisation process in the presence of an initiator and a catalyst. Polymers produced by this new process are also thought to be novel and may be used to derivatise biological molecules to improve their efficacy as therapeutic treatments. A preferred polymer is of formula The polymers are particularly suitable for derivatising proteins, such as interferon-?.

Abstract: Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient.

Abstract: Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided (among other things) are compositions comprising the conjugates, methods of making the conjugates, and methods of administering to a patient compositions comprising the conjugates.

Abstract: Provided herein are a coating or a device (e.g., absorbable stent) that includes a PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid biocompatible polymer and the methods of use thereof.

Abstract: The present invention provides compositions and processes for the solid phase synthesis of polypeptides. In particular, the present invention provides solid supports and processes for preparing solid supports for the synthesis of polypeptides.

Abstract: The invention discloses a porous composite biomaterial comprising of poly(?-glutamic acid)-g-chondroitin sulfate (?-PGA-g-CS) copolymer and poly(?-caprolactone). The composite biomaterial provides a three-dimensional microenvironment for using as a scaffold for tissue engineering and for supporting the attachment and proliferation of cells. The invention also discloses a method of producing a porous composite biomaterial.

Abstract: Methods of forming a bionanocomposite defining a shell and a core are generally provided along with the bionanocomposites themselves. The method includes non-covalently attaching biomacromolecules about a polymeric core such that the biomacromolecules cover at least about at least about 50% of the surface area of the polymeric core to form a shell. The polymeric core includes a polymer having pyridine functional groups. In one particular embodiment, the biomacromolecules can be attached to the polymeric core by combining an organic solution containing the polymer in an organic solvent with an aqueous solution containing the biomacromolecules to form an emulsion, mixing the emulsion, and removing the organic solvent.

Abstract: A biotag that includes a biomolecule that includes a bio polymer sequence; an attaching polymer attached at an endpoint of the biopolymer sequence; and a quantum dot bound to the attaching polymer causing the attaching polymer to become fluorescently labeled is provided. Suggested biomolecules include, but are not limited to, peptides, proteins, amino acids, nucleic acids, deoxyribonucleic acids, ribonucleic acids, and peptide nucleic acids. The biopolymer sequence may be or otherwise include a protein sequence. The biomolecule may be located inside a cell, outside a cell, or on a cell. Desirably, a quantum dot is bound to an attaching polymer and, thus the biomolecule, without using any of thiol chemistries, 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide/N-hydroxysuccinimide hydrochloride (EDC/NHS) chemistries, and biotin/avidin chemistries.

Abstract: Disclosed are water-soluble compositions of gemcitabine and docetaxel formed by conjugating the gemcitabine or docetaxel to a water-soluble polymer such as N-2-hydroxypropyl methacrylamide (HPMA). Also disclosed are methods of using the compositions of the invention for the treatment of cancer.

Abstract: The invention relates to composite materials that contain a polymer matrix and aggregates, and in some embodiments, methods of making, and methods of using these materials. Preferably, the aggregates are calcium phosphate aggregates. Preferably, the material is resistant to fracture. In further embodiments, the materials are used in surgical procedures of bone replacement. In further embodiments, the materials contain polyhedral silsesquioxanes and/or biodegradable segments. In further embodiments, the polymer matrix comprises biomolecules.

Abstract: A variety of products are obtained from modified guar protein extracts, for example, cosmetic or pharmacological or plant protective compositions or domestic care agents containing such products; these are particularly suitable for treating and/or modifying and/or coating the skin, hair, hard and textile surfaces and, notably, plant leaf surfaces.

Abstract: The present invention relates to a proteinaceous construct comprising a blood coagulation factor, e.g., Factor VIII (FVIII), being bound to at least one water soluble polymer, including a poly(alkylene oxide) such as polyethylene glycol (PEG). Further the present invention relates to methods of preparing PEGylated blood coagulation factor, e.g., FVIII, in the presence of bound antibodies. The invention also relates to methods for prolonging the in vivo-half-life of blood coagulation factor, e.g., FVIII, in the blood of a mammal having a bleeding disorder associated with functional defects or deficiencies of blood coagulation factor, e.g., FVIII.

Abstract: A resin composition includes a polyester capable of forming a crystal structure, and a substance represented by the following general structural formula (1), the substance represented by the following general structural formula (1) has a dehydration-condensed structure of two molecules of natural product-derived ?-amino acids or a substitution structure thereof, and the two molecules of ?-amino acids are not simultaneously glycine. In the above general structural formula, R1, R2, R3, and R4 indicate groups or substituent groups thereof bonded to the ? carbons of the ?-amino acids.

Abstract: Methods for reducing the T-cell mitogenicity of lectin compositions are provided. In one aspect this is achieved by chemically modifying mitogenic lectin compositions under optimized conditions. Additionally or alternatively, the reduction in T-cell mitogenicity is achieved by removing unmodified subunits chemically modified mixtures. Modified lectin compositions with reduced T-cell mitogenicity are also provided as are uses of the inventive compositions.

Abstract: In part, the present invention is directed to compositions and methods of making compositions comprising a polymeric backbone, a chelating group, a metal ion, and an active agent with a metal binding domain. The compositions can optionally further comprise protective groups. In part, the present invention is directed to prolonging the blood circulation time of an active agent containing a metal binding domain by using a composition comprising a polymeric backbone with a protective group, a chelator, and a metal ion.

Abstract: The invention provides reagents and methods for conjugating a polymer specifically to the ?-amine of a polypeptide. The invention provides monofunctional, bifunctional, and multifunctional PEGs and related polymers having a terminal thioester moiety capable of specifically conjugating to the ?-amine of a polypeptide having a cysteine or histidine residue at the N-terminus. The invention provides reactive thioester-terminated PEG polymers that have suitable reactivity with an N-terminal cysteine or histidine residue of a polypeptide to produce an amide bond between the PEG molecule and the polypeptide.

Abstract: The invention is directed to a multiblock copolymer with shape memory properties and a synthetic precursor of the multiblock copolymer 1. The multiblock copolymer contains: (i) a poly(depsipeptide) segment with an average molecular weight MW in the range of 1,000 to 20,000 g/mol; and (ii) a poly(?-caprolactone) segment with an average molecular weight MW in the range of 1,000 to 10,000 g/mol.

Abstract: The invention features grafted polymer systems for use in medical devices and/or for the delivery of active agents. The grafted polymers include at least one transport moiety, a linear backbone segment, and a pendant segment.

Abstract: Disclosed are compositions and methods for self-assembling polymeric particles by using biological binders attached to subunits of a multi-sectioned polymeric particle.

Abstract: Materials and methods for the generation of polyelectrolyte multilayers that can erode to release cationic components. The multilayers comprise layers that contain one or more cations and one or more charge-dynamic anionic polymers. Charge-dynamic anionic polymers contain side chains having removable functional groups. Removal of the functional groups results in a change in the net change in the charge of the polymer which can disrupt interactions between cations and the anionic polymers and facilitate release of cations.

Abstract: A new process for enhancing the hydrophilicity of the surface of a polyolefin or polyolefin copolymer article is characterized in that the surface is treated with an enzyme selected from oxidoreductases, especially of the cytochrome P450 family or enzymes classified as EC 1.13 or EC 1.14. The process is especially useful for the treatment of polypropylene films, fibres, or fabrics, inter alia for use in sanitary articles, threads, yarns, fabrics, textiles, garments, technical or household articles, printed or dyed cover films or packaging films.

Abstract: There are provided poly(vinyl alcohol) polymers and copolymers containing vinyl alcohol or vinyl acetate and derivatives thereof such as poly(ethylene glycol)-grafted poly(vinyl alcohol) polymers or polyether-grafted poly(vinyl alcohol) polymers. These polymers can contain various functional groups. Such polymers can be use as polymer matrix or solid support for various chemical substrates such as organic substrates and reagents. Cross-linked poly(vinyl alcohol) polymers and copolymers are also provided. Methods for preparing such polymers as well as several of their uses are also included.

Abstract: Novel carbosilane dendrimers, their preparation and their uses. The dendrimers of the invention have secondary, tertiary and quaternary amino groups at their branch ends. Their possible uses include vehicles for carrying anionic-charged molecules in the blood, such as nucleic acids, among them ODN and RNAi, and other anionic drugs with which they have the capacity of interacting, protecting them from interaction with plasma protein and/or increasing their penetration rate in target cells. In the cases where the bond is long-lasting, the dendrimers of the invention can be used to fix anionic molecules to surfaces. Their uses also include their administration as active ingredients to prevent or treat diseases caused by micro-organisms with whose structure and/or life cycle they interfere.

Abstract: The invention relates generally to polyvalent macromolecules comprising: (a) a polymer backbone and (b) pendent groups attached to said polymer backbone, wherein some or all of said pendent groups comprise: (i) optionally a linker, (ii) a surface-seeking group, which is capable of binding strongly to a metal surface, (iii) optionally a chromophore, which is detectable by at least one spectroscopic method. Such molecules can modify metal surfaces and have a variety of uses including (without limitation) appending chromophores to metal surfaces without the need to establish complex chemistry; for the stabilisation and labelling of metal nanoparticles; and for preparing and aggregating nanoparticles in a controlled fashion.

Abstract: The present invention relates to a method for immobilization of a biologically active polypeptide using maltose binding protein (MBP) and a biologically active solid substrate on which a biologically active polypeptide is immobilized by the above method. More particularly, the present invention relates to a method for immobilization of a biologically active polypeptide comprising the following steps; 1) preparing a fusion protein by linking a biologically active polypeptide to carboxyl terminal of maltose binding protein (MBP); and 2) immobilizing the fusion protein on the hydrophobic surface by physical adsorption of amino terminal containing hydrophobic domain exposed on the surface of maltose binding protein on the hydrophobic surface of a solid substrate, and a biologically active solid substrate on which a biologically active polypeptide is immobilized by the said method.

Abstract: Novel site-specific mono-conjugates of Granulocyte Colony Stimulating Factor (G-CSF) are hereby described, with analogues and derivatives thereof, which stimulate proliferation and differentiation of progenitor cells to mature neutrophiles. These conjugates have been obtained using transglutaminase to covalently and site-specifically bind a hydrophilic, non-immunogenic polymer to a single glutamine residue of the human G-CSF native sequence and analogues thereof. These novel site-specific mono-conjugated derivatives are recommended for therapeutic use since they are stable in solution and exhibit significant biological activity in vitro and a longer bloodstream half-life, as compared to the non-conjugated protein, with a consequent prolonged pharmacological activity.

Abstract: A method for stabilizing a protein by adding a copolymer to a composition containing the protein where the copolymer has: a repeating unit (A) represented by the following formula (1) and a repeating unit (B) represented by the following formula (2): wherein R1, R2, R3 and R4 are defined in the description.

Abstract: The present invention is directed to a method of producing nanoparticles and nanoparticles obtainable by that method. The invention further relates to a pharmaceutical composition, comprising said nanoparticles and the use of the nanoparticles for the treatment of diseases and conditions, requiring a pharmaceutical agent to cross one or more physiological barriers.

Abstract: The present invention provides, among other things, segmented, degradable polymeric reagents suitable for reaction with biologically active agents to form conjugates, the polymeric reagents comprising one or more polymer chains divided or separated by one or more degradable linkages into polymer segments having a molecular weight suitable for renal clearance. The polymeric reagents can have a substantially linear structure, a branched structure, or a multiarm structure. Each structure includes one or more linkages capable of degradation in vivo.

Abstract: A water soluble polymer comprising multiple degradable carbonate linkages in a backbone and, for each carbonate linkage in the backbone, an oligomer linked thereto by the carbonate linkage, wherein the oligomer is branched.

Abstract: The invention provides metal-chelating poly(ether amide) polymers useful in preparation of polymer compositions for delivering a variety of cargo molecules, such as bioactive agents. In solution metal ions and cargo molecules, such as vaccine epitopes, that include metal avid amino acids can be loaded into the polymer compositions and held in a non-covalent complex. Nanoparticles of such polymer compositions can also be prepared directly from the solution.

Abstract: A method of protecting hair by covalently bonding to the hair a polymeric compound comprising polyethylene glycol.

Abstract: Disclosed is a cross-linked branched poly(alkylenimine) and compositions thereof and nucleotide molecules. Also disclosed are methods for preparing the cross-linked branched poly(alkylenimine).

Abstract: A water-soluble photo-activatable polymer including: a photo-activatable group adapted to be activated by an irradiation source and to form a covalent bond between the water-soluble photo-activatable polymer and a matrix having at least one carbon; a reactive group adapted to covalently react with a biomaterial for subsequent delivery of the biomaterial to a cell; a hydrophilic group; and a polymer precursor. A composition including a monomolecular layer of the water-soluble photo-activatable polymer and a matrix having at least one carbon, wherein the monomolecular layer is covalently attached to the matrix by a covalent bond between the photo-activatable group and the at least one carbon. The composition further includes a biomaterial having a plurality of active groups, wherein the biomaterial is covalently attached to the monomolecular layer by covalent bonding between the active groups and reactive groups. Also provided is a method for delivery of a biomaterial to a cell.

Abstract: The present invention relates to a polymer matrix for specifically tethering surface epitopes or receptors of cells, said polymer matrix having been pretreated by molecular imprinting. The invention also relates to a method of producing such a polymer matrix. The polymer matrices according to the present invention are used in therapeutic and diagnostic applications as well as for isolating cells.

Abstract: The present invention relates to activated polymer substrates capable of binding functional biological molecules, to polymer substrates comprising bound and functional biological molecules, to devices comprising such substrates and to methods of producing them.

Abstract: A biocompatible, biodegradable, macromolecular water-absorbent hybrid material (WAHM), having a three-dimensional configuration with intermolecular covalent bonds and containing free functional groups, said polymer being formed by polymer-polymer intercoupling reaction between a natural water-soluble polymer A or its derivatives having a molecular weight between 20,000 and 300,000 Da, and a synthetic polymer B in an adequate ratio wherein the natural polymer A is selected from amphoteric reactants, partially denatured or chemically modified natural polymer, that dissociates in water to form both anions and cations, and which can undergo polymer-polymer intercoupling reactions, and wherein synthetic polymer B s a linear or branched reactive synthetic copolymer having a molecular weight of 50,000-500,000 Da derived from a vinyl monomer and an ethylenically unsaturated monomer, having a backbone with polymeric subunits covalently bonded to the polymer backbone, the subunits comprising ones with non-reactive and